Long Non-Coding RNA A2M-AS1 Promotes Breast Cancer Progression by Sponging microRNA-146b to Upregulate MUC19

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Ahmed S, Pati S, Le D, Haider K, Iqbal N. The prognostic and predictive role of 21-gene recurrence scores in hormone receptor-positive early-stage breast cancer. J Surg Oncol. 2020;122(2):144–154. doi:10.1002/jso.2595232346902
   PubMed Web of Science ®Google Scholar
• Ferreira Almeida C, Oliveira A, Joao Ramos M, Fernandes PA, Teixeira N, Amaral C. Estrogen receptor-positive (ER(+)) breast cancer treatment: are multi-target compounds the next promising approach? Biochem Pharmacol. 2020;177:113989. doi:10.1016/j.bcp.2020.11398932330493
   PubMed Web of Science ®Google Scholar
• Annaratone L, Cascardi E, Vissio E, et al. The multifaceted nature of tumor microenvironment in breast carcinomas. Pathobiology. 2020;87(2):125–142. doi:10.1159/00050705532325459
   PubMed Web of Science ®Google Scholar
• Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38. doi:10.1186/1476-4598-10-3821489289
   PubMed Web of Science ®Google Scholar
• Giulietti M, Righetti A, Principato G, Piva F. LncRNA co-expression network analysis reveals novel biomarkers for pancreatic cancer. Carcinogenesis. 2018;39(8):1016–1025. doi:10.1093/carcin/bgy06929796634
   PubMed Web of Science ®Google Scholar
• Fang K, Caixia H, Xiufen Z, Zijian G, Li L. Screening of a novel upregulated lncRNA, A2M-AS1, that promotes invasion and migration and signifies poor prognosis in breast cancer. Biomed Res Int. 2020;2020:9747826. doi:10.1155/2020/974782632352014
   PubMed Web of Science ®Google Scholar
• Yamamura S, Imai-Sumida M, Tanaka Y, Dahiya R. Interaction and cross-talk between non-coding RNAs. Cell Mol Life Sci. 2018;75(3):467–484.28840253
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–222. doi:10.1038/nrd.2016.24628209991
   PubMed Web of Science ®Google Scholar
• Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res. 2009;69(4):1279–1283. doi:10.1158/0008-5472.CAN-08-355919190326
   PubMed Web of Science ®Google Scholar
• Torres MP, Chakraborty S, Souchek J, Batra SK. Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des. 2012;18(17):2472–2481. doi:10.2174/1381612811209247222372499
   PubMed Web of Science ®Google Scholar
• Do SI, Kim K, Kim DH, et al. Associations between the expression of mucins (MUC1, MUC2, MUC5AC, and MUC6) and clinicopathologic parameters of human breast ductal carcinomas. J Breast Cancer. 2013;16(2):152–158. doi:10.4048/jbc.2013.16.2.15223843846
   PubMed Web of Science ®Google Scholar
• Astashchanka A, Shroka TM, Jacobsen BM. Mucin 2 (MUC2) modulates the aggressiveness of breast cancer. Breast Cancer Res Treat. 2019;173(2):289–299. doi:10.1007/s10549-018-4989-230317423
   PubMed Web of Science ®Google Scholar
• Alam M, Bouillez A, Tagde A, et al. MUC1-C represses the crumbs complex polarity factor CRB3 and downregulates the Hippo pathway. Mol Cancer Res. 2016;14(12):1266–1276. doi:10.1158/1541-7786.MCR-16-023327658423
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang S, Wang Z, et al. Estrogen regulates Hippo signaling via GPER in breast cancer. J Clin Invest. 2015;125(5):2123–2135. doi:10.1172/JCI7957325893606
   PubMed Web of Science ®Google Scholar
• Matamala N, Vargas MT, Gonzalez-Campora R, et al. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem. 2015;61(8):1098–1106. doi:10.1373/clinchem.2015.23869126056355
   PubMed Web of Science ®Google Scholar
• Crudele F, Bianchi N, Reali E, Galasso M, Agnoletto C, Volinia S. The network of non-coding RNAs and their molecular targets in breast cancer. Mol Cancer. 2020;19(1):61.32188472
   PubMed Web of Science ®Google Scholar
• Amelio I, Bernassola F, Candi E. Emerging roles of long non-coding RNAs in breast cancer biology and management. Semin Cancer Biol. 2020. doi:10.1016/j.semcancer.2020.06.019
   PubMed Web of Science ®Google Scholar
• Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353–358. doi:10.1016/j.cell.2011.07.01421802130
   PubMed Web of Science ®Google Scholar
• Abdollahzadeh R, Daraei A, Mansoori Y, Sepahvand M, Amoli MM, Tavakkoly-Bazzaz J. Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: a new look at hallmarks of breast cancer. J Cell Physiol. 2019;234(7):10080–10100. doi:10.1002/jcp.2794130537129
   PubMed Web of Science ®Google Scholar
• Yang E, Xue L, Li Z, Yi T. Lnc-AL445665. 1–4 may be involved in the development of multiple uterine leiomyoma through interacting with miR-146b-5p. BMC Cancer. 2019;19(1):709. doi:10.1186/s12885-019-5775-131319799
   PubMed Web of Science ®Google Scholar
• Zhang E, Li X. LncRNA SOX2-OT regulates proliferation and metastasis of nasopharyngeal carcinoma cells through miR-146b-5p/HNRNPA2B1 pathway. J Cell Biochem. 2019;120(10):16575–16588. doi:10.1002/jcb.2891731099048
   PubMed Web of Science ®Google Scholar
• Katakowski M, Buller B, Zheng X, et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 2013;335(1):201–204. doi:10.1016/j.canlet.2013.02.01923419525
   PubMed Web of Science ®Google Scholar
• Li C, Miao R, Liu S, et al. Down-regulation of miR-146b-5p by long noncoding RNA MALAT1 in hepatocellular carcinoma promotes cancer growth and metastasis. Oncotarget. 2017;8(17):28683–28695. doi:10.18632/oncotarget.1564028404923
   PubMedGoogle Scholar
• Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK. Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta. 2011;1815(2):224–240.21277939
   PubMed Web of Science ®Google Scholar
• Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9(12):874–885. doi:10.1038/nrc276119935676
   PubMed Web of Science ®Google Scholar
• Mercogliano MF, De Martino M, Venturutti L, et al. TNFalpha-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. Clin Cancer Res. 2017;23(3):636–648. doi:10.1158/1078-0432.CCR-16-097027698002
   PubMed Web of Science ®Google Scholar
• Ideo H, Hinoda Y, Sakai K, et al. Expression of mucin 1 possessing a 3ʹ-sulfated core1 in recurrent and metastatic breast cancer. Int J Cancer. 2015;137(7):1652–1660. doi:10.1002/ijc.2952025787775
   PubMed Web of Science ®Google Scholar
• Song L, Xiao Y. Downregulation of hsa_circ_0007534 suppresses breast cancer cell proliferation and invasion by targeting miR-593/MUC19 signal pathway. Biochem Biophys Res Commun. 2018;503(4):2603–2610. doi:10.1016/j.bbrc.2018.08.00730139516
   PubMed Web of Science ®Google Scholar
• Wu L, Yang X. Targeting the Hippo pathway for breast cancer therapy. Cancers (Basel). 2018;10(11):422. doi:10.3390/cancers10110422
   PubMed Web of Science ®Google Scholar
• Shi P, Feng J, Chen C. Hippo pathway in mammary gland development and breast cancer. Acta Biochim Biophys Sin (Shanghai). 2015;47(1):53–59. doi:10.1093/abbs/gmu11425467757
   PubMed Web of Science ®Google Scholar